Literature DB >> 19439017

In situ deposition of complement in human acute brain ischaemia.

E D Pedersen1, E M Løberg, E Vege, M R Daha, J Maehlen, T E Mollnes.   

Abstract

Experimental animal models indicate that complement contributes to tissue damage during brain ischaemia and stroke, but limited data are available for a role of the complement in human stroke. We, therefore, evaluated whether acute ischaemia leads to complement activation in human brain. Indirect immunohistochemical staining was performed on paraffin-embedded, formalin-fixed human brain from 10 patients and 10 controls. Complement components C1q, C3c and C4d were detected in all ischaemic lesions, suggesting activation via the classical pathway. C9, C-reactive protein and IgM were detected in necrotic zones. Marked CD59 and weak CD55 expression were found in normal brains, but these complement regulators were virtually absent in ischaemic lesions. Modest amounts of mannose-binding lectin (MBL), MBL-associated serine protease-2 and factor B were found in both ischaemic lesions and controls. These data suggest that increased deposition of complement components combined with decreased expression of complement regulators is a possible mechanism of tissue damage during ischaemia in human brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439017     DOI: 10.1111/j.1365-3083.2009.02253.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  28 in total

1.  Ficolin-1 Levels in Patients Developing Vasospasm and Cerebral Ischemia After Spontaneous Subarachnoid Hemorrhage.

Authors:  Laura Llull; Steffen Thiel; Sergio Amaro; Álvaro Cervera; Anna M Planas; Ángel Chamorro
Journal:  Mol Neurobiol       Date:  2016-10-12       Impact factor: 5.590

2.  The contribution of mannose binding lectin to reperfusion injury after ischemic stroke.

Authors:  Helena Morrison; Jennifer Frye; Grace Davis-Gorman; Janet Funk; Paul McDonagh; Gregory Stahl; Leslie Ritter
Journal:  Curr Neurovasc Res       Date:  2011-02       Impact factor: 1.990

Review 3.  The Immune Response to Acute Focal Cerebral Ischemia and Associated Post-stroke Immunodepression: A Focused Review.

Authors:  Bolanle M Famakin
Journal:  Aging Dis       Date:  2014-10-01       Impact factor: 6.745

4.  Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice.

Authors:  Andrew Elvington; Carl Atkinson; Liudmila Kulik; Hong Zhu; Jin Yu; Mark S Kindy; V Michael Holers; Stephen Tomlinson
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

Review 5.  Complement in the brain.

Authors:  Robert Veerhuis; Henrietta M Nielsen; Andrea J Tenner
Journal:  Mol Immunol       Date:  2011-05-04       Impact factor: 4.407

Review 6.  Injury site-specific targeting of complement inhibitors for treating stroke.

Authors:  Ali Alawieh; Stephen Tomlinson
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

7.  High serum complement component C4 as a unique predictor of unfavorable outcomes in diabetic stroke.

Authors:  Ximeng Zhang; Jun Yin; Kai Shao; Le Yang; Wei Liu; Yiqing Wang; Shanshan Diao; Shicun Huang; Qun Xue; Jianqiang Ni; Yi Yang
Journal:  Metab Brain Dis       Date:  2021-09-04       Impact factor: 3.584

8.  Is plasma C3 and C4 levels useful in young cerebral ischemic stroke patients? Associations with prognosis at 3 months.

Authors:  Bin Zhang; Ning Yang; Cong Gao
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

9.  Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice.

Authors:  Denise Harhausen; Uldus Khojasteh; Philip F Stahel; B Paul Morgan; Wilfried Nietfeld; Ulrich Dirnagl; George Trendelenburg
Journal:  J Neuroinflammation       Date:  2010-03-04       Impact factor: 8.322

10.  PMX53 protects spinal cord from ischemia-reperfusion injury in rats in the short term.

Authors:  Q Dong; L Sun; L Peng; B Yan; J Lv; G Wang; S Gong
Journal:  Spinal Cord       Date:  2015-09-08       Impact factor: 2.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.